Zuellig Pharma: A Sustainable Approach to Healthcare Access Through Innovative Solutions
BioSpectrum Asia|October 2024
The equitable distribution of medicines and their accessibility are critical to the resilience of the healthcare system.
Zuellig Pharma: A Sustainable Approach to Healthcare Access Through Innovative Solutions

However, disparities in access and equity continue to exist and these are pertinent to address, especially as healthcare disruptions can negatively impact an economy's public health and patient care.

As powerful catalysts of transformational change, the COVID-19 pandemic tested the resilience and flexibility of pharmaceutical supply chains. In the wake of the pandemic, the healthcare sector requires an agile and robust supply chain risk management system to address disruptions, ensure resilience, and smooth operations.

In recent years, supply chain risk management practices have been revolutionised by technology, with new innovations and risk management solutions reducing accessibility concerns through real-time insights and data-driven mitigation strategies. The use of disruptive technologies and Supply Chain Risk Management (SCRM) can help minimise risks by identifying disruptions, preparing contingency plans, and alleviating their overall impact.

Strengthening Healthcare SCRM Strategies to Overcome Accessibility Disparities

Blockchain-enabled healthcare supply chains and IoT sensors facilitate comprehensive, secure, and traceable real-time risk assessments. Predictive analytics and artificial intelligence algorithms can help identify and mitigate disruptions, ensuring patient accessibility.

Zuellig Pharma, a leading healthcare solutions company with a purpose of making healthcare more accessible, harnesses the transformative potential of disruptive technologies to enhance supply chain resilience, agility, and responsiveness to risks, developing a connected pharmaceutical ecosystem through innovative digital platforms.

This story is from the {{IssueName}} edition of {{MagazineName}}.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the {{IssueName}} edition of {{MagazineName}}.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView all
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024